The estimated Net Worth of James E Deerfield Mgmt L.P.... is at least $31.6 Million dollars as of 26 April 2017. James P owns over 426,954 units of Zafgen stock worth over $868,830 and over the last 9 years James sold ZFGN stock worth over $30,715,737.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
James P ZFGN stock SEC Form 4 insiders trading
James has made over 18 trades of the Zafgen stock since 2015, according to the Form 4 filled with the SEC. Most recently James sold 426,954 units of ZFGN stock worth $4,978,284 on 26 April 2017.
The largest trade James's ever made was selling 756,852 units of Zafgen stock on 24 June 2015 worth over $1,718,054. On average, James trades about 307,789 units every 38 days since 2015. As of 26 April 2017 James still owns at least 877,606 units of Zafgen stock.
You can see the complete history of James P stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Zafgen
Over the last 10 years, insiders at Zafgen have traded over $14,218,922 worth of Zafgen stock and bought 689,531 units worth $3,998,442 . The most active insiders traders include James E Deerfield Mgmt L.P...., Bruce Booth, and Kevin P Starr. On average, Zafgen executives and independent directors trade stock every 53 days with the average trade being worth of $87,516. The most recent stock trade was executed by Thomas E. Hughes on 28 June 2018, trading 32,000 units of ZFGN stock currently worth $320,000.
What does Zafgen do?
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.
What does Zafgen's logo look like?
Complete history of James P stock trades at Antares Pharma Inc, eHealth Inc, and Zafgen
Zafgen executives and stock owners
Zafgen executives and other stock owners filed with the SEC include:
-
Brian McVeigh,
Chief Business Officer -
Frank Thomas,
Independent Director -
Thomas Daniel,
Independent Director -
Jonathan Leff,
Director -
Thomas Hamilton,
Director -
Priya Singhal,
Head of Research and Development -
Michael Celano,
Chief Financial Officer -
Carole Ben-Maimon,
President, Chief Executive Officer, Director -
Joseph Truitt,
Chairman of the Board -
Patrick Loustau,
President -
Cameron Geoffrey Mc Donough,
Director -
Frances K Heller,
Director -
Robert J Perez,
Director -
John L Lamattina,
Director -
Dennis D Kim,
Chief Medical Officer -
Alicia Secor,
Chief Commercial Officer -
James E Deerfield Mgmt L.P....,
-
Bruce Booth,
Director -
Patricia L Allen,
Chief Financial Officer -
James E Deerfield Mgmt L.P....,
-
Jeffrey S. Hatfield,
Chief Executive Officer -
Wendy Everett,
Director -
Venture Fund Vii L P Atlas ...,
-
Peter Barrett,
Director -
Avi Y. Goldberg,
Director -
Rock Ventures Lp Third Rock...,
-
Rock Ventures Lp Third Rock...,
-
Thomas E. Hughes,
Chief Executive Officer -
Kevin P Starr,
Director